Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Open accessPublished version of a preprint
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 6×
“127 Interval between symptoms onset and RTPCR testing, median (p25-p75), days 3 [2, 4] 3 [1, 4] 0.”
BackgroundInfluentialVoysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00152-0 · Cited by 1,237
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., Miller, J., Schrag, S. J., & Verani, J. R. (2022) · JAMA · doi:10.1001/jama.2022.0470 · Cited by 628
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435
Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Malik, A. A., De la Cruz, E., Jorge, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01705-6 · Cited by 401
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380
McMenamin, M. E., Nealon, J., Lin, Y., Wong, J. Y., Cheung, J. K., Lau, E. H. Y., Wu, P., Leung, G. M., & Cowling, B. J. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00345-0 · Cited by 360
Research works printed but not linked: 21
- Ranzani, O. T. et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. https://doi.org/10.1136/bmj.n2015 (2021). · DOI · Paper page
- Cerqueira-Silva, T. et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat. Med. https://doi.org/10.1038/s41591-022-01701-w (2022). · DOI · Paper page
- Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2119451 (2022). · doi:10.1056/nejmoa2119451 · Paper page
- Strategic Advisory Group of Experts on Immunization—SAGE (WHO). Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, 4-7 October 2021. (2021).
- Dolgin, E. Omicron thwarts some of the world’s most-used COVID vaccines. Nature 601, 311–311 (2022). · DOI
- Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med 28, 486–489 (2022). · DOI · Paper page
- Lu, L. et al. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clin. Infect. Dis. ciab1041 https://doi.org/10.1093/cid/ciab1041 (2021). · DOI · Paper page
- Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399, 521–529 (2022). · DOI · Paper page
- Zeng, G. et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis. 22, 483–495 (2022). · DOI · Paper page
- Jara, A. et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob. Health 10, e798–e806 (2022). · DOI · Paper page
- Hitchings, M. D. T. et al. Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study. BMJ e070102 https://doi.org/10.1136/bmj-2022-070102 (2022). · DOI
- Kahn, R., Schrag, S. J., Verani, J. R. & Lipsitch, M. Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. Am. J. Epidemiol. 191, 800–811 (2022). · DOI · Paper page
- Bodner, K., Knight, J., Hamilton, M. A. & Mishra, S. Higher contact among vaccinated can be a mechanism for negative vaccine effectiveness. https://doi.org/10.1101/2022.04.25.22274266 (2022). · DOI
- Kaslow, D. C. Force of infection: a determinant of vaccine efficacy? npj Vaccines 6, 51 (2021). · DOI
- Bastos, L. S. et al. COVID-19 and hospitalizations for SARI in Brazil: a comparison up to the 12th epidemiological week of 2020. Cad. Saúde. Pública 36, e00070120 (2020). · doi:10.1590/0102-311x00070120
- Sullivan, S. G., Tchetgen Tchetgen, E. J. & Cowling, B. J. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. Am. J. Epidemiol. 184, 345–353 (2016). · DOI · Paper page
- Andrejko, K. L. et al. Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California. Clin. Infect. Dis. 74, 1382–1389 (2022). · DOI · Paper page
- Chua, H. et al. The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology. Epidemiology 31, 43–64 (2020). · DOI · Paper page
- Foppa, I. M. et al. The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings. Int. J. Epidemiol. dyw022 https://doi.org/10.1093/ije/dyw022 (2016). · DOI
- Thompson, M. G. et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N. Engl. J. Med 385, 1355–1371 (2021). · DOI · Paper page
- Hitchings, M. D. T. et al. Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case–Control Studies of COVID-19 Vaccine Effectiveness. Epidemiology 33, 450–456 (2022). · DOI
Cited by
Modeling transmission of SARS-CoV-2 Omicron in China
Cai, J., Deng, X., Yang, J., Sun, K., Liu, H., Chen, Z., Peng, C., Chen, X., Wu, Q., Zou, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01855-7 · Cited by 281
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity: A Systematic Review and Meta-analysis
Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d'Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10650 · Cited by 280
Au, W. Y., & Cheung, P. P.-H. (2022) · BMJ · doi:10.1136/bmj-2022-069989 · Cited by 143
Neutralising antibodies predict protection from severe COVID-19
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · doi:10.1101/2022.06.09.22275942 · Cited by 139
Feikin, D. R., Abu-Raddad, L. J., Andrews, N., Davies, M.-A., Higdon, M. M., Orenstein, W. A., & Patel, M. K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.069 · Cited by 83
Metadata
- Authors
- Ranzani, O. T., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R. F. C., Almiron, M., de Oliveira, R. D., Cummings, D. A. T., Dean, N. E., Andrews, J. R., Ko, A. I., & Croda, J.
- Venue
- Nature Communications
- Published
- 2022-10-06
- Volume
- 13
- Issue
- 1
- Pages
- 5536-5536
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4302293777
- Cited by
- 111
- References
- 14
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. https://app.cochat.ai/papers/10.1038/s41467-022-33169-0
- The paper
- Ranzani, O. T., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R. F. C., Almiron, M., de Oliveira, R. D., Cummings, D. A. T., Dean, N. E., Andrews, J. R., Ko, A. I., & Croda, J. (2022). Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature Communications. https://doi.org/10.1038/s41467-022-33169-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.